Topic:Vaccine development
Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 2 virus. Serological responses following two and three doses of an inactivated equid herpesvirus 1 ( EHV -1) vaccine containing a subtype 1 strain were examined in yearling ponies. Complement fixing antibody responses were significantly higher against the subtype 1 vaccine strain than against a subtype 2 virus. Complement fixing antibody responses declined rapidly after the second dose of vaccine and had returned to almost pre-vaccination levels eight weeks after the second dose of vaccine. Complement fixing antibody titres to the heterologous subtype 2 strain increased after each successive dose of va...
Equine immunology 4: vaccines and antisera. This paper attempts to relate the practicalities of vaccine development to the ideals which should be aimed for in a new vaccine. The type of immune response induced is dependent upon the nature of the antigen in the vaccine and the site and timing of its presentation to the immune system. In this respect the influence of age, maternal immunity and antigenic competition are discussed. The possible side effects associated with vaccination are defined and vaccines which are currently available for horses are reviewed. These vaccines are mostly for the prevention of respiratory disease. Finally, ...
Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine. Serological responses to three bivalent aqueous equine influenza vaccines of different potency and an adjuvanted bivalent vaccine containing inactivated A/equine/Prague/56 (H7N7) and A/equine/Miami/63 (H3N8) viruses, were examined in seronegative ponies. Potencies of the vaccines, measured by single-radial-diffusion tests, ranged from 4 to 56 micrograms of haemagglutinin (HA) antigen activity/virus strain per dose. Serological responses to vaccination were examined by haemagglutination-inhibition (HI) and single-radial-haemolysis (SRH) tests. Four weeks after a primary dose, HI responses to bo...
Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8). Forty ponies immunized with inactivated virus vaccine containing A/equine/Miami/63 (H3N8) virus and six unvaccinated, seronegative ponies were experimentally challenged with a representative of recent equine H3N8 virus isolates, A/equine/Newmarket/79. All unvaccinated ponies became infected as judged by virus excretion, febrile responses and antibody responses, but only two of the vaccinated ponies were fully protected. Pre-challenge antibody levels to A/Newmarket/79 virus detected by single radial haemolysis (SRH) correlated well with the degree of clinical protection but the levels required ...
Analysis of antigenic variation in equine 2 influenza A viruses. Influenza outbreaks involving viruses of the H3N8 subtype (equine 2) often occur in vaccinated horses. For this reason, a series of influenza viruses of the H3N8 subtype were examined to determine if antigenic variation could be detected in isolates during the period 1963-81. Antigenic analyses with post-infection ferret sera and monoclonal antibodies showed that the haemagglutinins of recent isolates were antigenically distinguishable from the prototype A/eq/Miami/1/63 and that antigenically distinguishable groups of equine 2 viruses co-circulate in the horse population. Based on these studie...
Venezuelan equine encephalomyelitis virus: concentration, partial purification, inactivation and immunogenicity. Venezuelan equine encephalomyelitis (VEE) TC-84 vaccinal virus, from 10-1. quantities of infected duck embryo fibroblast cell culture fluids, was isolated by combined continuous-flow centrifugation with isopycnic banding in sucrose. Most of the recovered infectivity and hemagglutinating activity were in a single band at a buoyant density (rho) of 1.2. About 90% of the total input protein (450-520 mg) was removed with the effluent, whereas most of the remaining 10% also banded at a rho of 1.2. Infectivity was inactivated with formalin at a final concentration of 0.05% at 37 degrees C for 24 hr....
Immunogenicity of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) following inactivation by betapropiolactone (BPL) and ultraviolet (UV) light. Some kinetic data on the inactivation of equine herpesvirus type 1 (EHV1) and equine rhinovirus type 1 (ERhV1) by betapropiolactone (BPL) and ultraviolet (UV) irradiation are reported. 0.25% BPL at 37 degrees C for 1 h reduced the titre of EHV1 by greater than 10(3 . 4) and of ERhV1 by greater than 10(4 . 1) TCID50/ml. UV irradiation (334 microW/cm2) produced similar reductions in titre after 2 min. These data were used as a basis for inactivating EHV1 and ERhV1 by the combined action of BPL and UV irradiation. Viruses were exposed to 0.1% BPL for 1 h at 4 degrees C with constant stirring, fol...
Respiratory tract immune response to microbial pathogens. Effective resistance to respiratory tract infection depends principally on specific immunity on mucosal surfaces of the upper or lower respiratory tract. Respiratory tract immune response comprises antibody and cell-mediated systems and may be induced most readily by surface presentation of replicating agents but can result from parenteral or local presentation of highly immunogenic antigens. Upper and lower respiratory tract systems differ in immunologic competence, with the lungs having a greater inventory of protective mechanisms than the trachea or nose. Several effective vaccines have bee...
Enhancement of Naja naja atra antivenin production in horses. As the conventional hyperimmunization schedule in horses introduced by Tanaka could not produce enough neutralizing antibody against Naja naja atra venom, the mixture of Carboxymethyl cellulose (CMC)-Cobra venom incorporated with adjuvant was used for immunization. The neutralizing antibody produced (30 LD50) seemed to be increased but still not to reach the satisfactory level. By using CMC-Cobratoxin adjuvant mixture as an immunizing agent, highly potent antivenin (220 LD50) was obtained.
Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus I. A chemically inactivated, adjuvanted vaccine prepared from a virulent strain of Equine herpesvirus I (EHV-I) was used to immunize pregnant Thoroughbred broodmares during a five-year field test designed to determine its safety and efficacy. Each mare in the vaccinated groups received 3 intramuscular injections of vaccine beginning immediately prior to and during the last half of pregnancy. Vaccine was injected at approximately 60-day intervals. The accumulated incidence of EHV-I abortions among vaccinated mares during the field trial period was 1.6/1000 as compared with an incidence of 6.8/1000...
Antigenic properties of some equine influenza viruses. The antigenic relationships between the haemagglutinins of five A/equine-1 viruses and between six A/equine-2 viruses were examined using post-infection ferret and immunized pony sera. Similar results were obtained with sera from both species for the A/equine-1 viruses and these confirmed minor antigenic differences between the prototype A/Prague 1/56 virus and viruses isolated in England in 1973 and 1977. Considerable antigenic differences were found between five of the A/equine-2 viruses, using ferret sera, but these differences were less evident using pony sera. The response of ponies to th...
A summary of antibody titration experiments in some animal species treated with ERA vaccine and an inactivated rabies vaccine. The results of antibody titrations in different animal species vaccinated against rabies are reported. The following points are considered: (1) antibody titration may be used to detect an immunity status in dogs, (2) equines should be vaccinated in infected areas, (3) experiments in progress are comparing ERA vaccine and an inactivated vaccine in bovines, and (4) the vaccination of fallow deer (Dama dama) and moufflons (Ovis ammon musimon) produced results suggesting an extension of the experiment with the purpose of vaccinating wild ruminants whenever possible.
Mechanisms of infection in the respiratory tract. Related to its potential vulnerability the respiratory tract has a very complex and effective defence apparatus. The interaction between these defence mechanisms and certain characteristics of aetiological agents results in a pattern in which initial infections by these agents tend to occur at specific sites in the tract. Infections in which the primary portal of entry is in the upper respiratory tract include Bordetella bronchiseptica and Haemophilus spp in pigs; Pasteurella spp in cattle, sheep, pigs; Mycoplasma spp in cattle, sheep, pigs and poultry; equine herpesvirus 1 in horses; infectio...
Stability of viability and immunizing potency of lyophilized, modified equine arteritis live-virus vaccine. The Bucyrus strain of equine arteritis virus, previously modified to avirulence and vaccinal virus by 131 serial passages in primary cell cultures of horse kidney followed by 111 passages in primary cell cultures of rabbit kidney, was further passaged in cultures of the E. Derm (NBL-6) cell line, a continuous diploid cell line. Pools of the 16th and 25th passages of the virus in this last equine dermal cell line were lyophilized and stored in lots at 37 C, 23 to 28 C, 4C, and -20 C. The viability of the vaccinal virus deteriorated rapidly during storage at 37 C and at 23 to 28 C, but was relat...
Active immunisation of horses against tetanus including the booster dose and its application. Successful active immunisation of horses against tetanus is dependent on a number of factors of which the toxoid preparation used, its method of application and the ability of the individual horse to respond are fundamental. Two immunisation schedules using an aluminium-based toxoid preparation were examined and the protection determined by monitoring the level of antitoxin afforded by each schedule. The results obtained demonstrated that 2 doses of this toxoid are necessary to ensure 12 months protection in all horses. These results are discussed in relation to the factors involved in active ...
[Inactivated vaccines against rhinopneumonitis in horses]. Attempts were made to produce inactivated vaccines against horse Herpes virus 1, using various inactivating agents and adjuvants, Best results were obtained with vaccine No 3 (glutaraldehide inactivator and "CTC" adjuvant). Used were two strains of the virus (St. Karaja and Varna). isolated in this country in cell cultures of a sucking pig kidney. Vaccine No 3 showed good immunogenic properties. Its application resulted in the full cease of abortions and respiratory diseases on the base of infection with the horse Herpes virus 1. The vaccination protects newborn colts from rhinopneumonitis if ...
Serologic responses of pregnant thoroughbred mares to vaccination with an inactivated equine herpesvirus 1 vaccine. The immunogenic potency and safety of a chemically inactivated equine herpesvirus 1 vaccine with added adjuvant was evaluated by testing serum-neutralizing and complement-fixation antibody responses of pregnant Thoroughbred mares. The vaccinated population comprised 321 pregnant mares on 7 farms; 3 in Normandy, France; 1 in Kildare, Ireland; and 3 in central Kentucky. The pattern of antibody response to vaccination was found qualitatively and quantitatively similar to that of pregnant mares previously vaccinated and determined by challenge exposure to be immune to abortigenic infection under e...
Response of pregnant mares to equine herpesvirus 1 (EHV1). Twenty-one pregnant mares were inoculated with EHV1. Nineteen became infected as evidenced by clinical signs and/or viremia but only one mare aborted a virus-infected fetus. The viremias were leukocyte-associated and appeared to be non-productive, latent infections of these cells. Infectivity, detectable by cocultivation, persisted in the circulating leukocytes for as long as 9 days without resulting in abortion. The data suggest that it is extremely difficult to evaluate the efficacy of vaccines in preventing EHV1 (Rhinopneumonitis) abortion due to the paucity of non-exposed mares, lack of te...
Combined active-passive immunisation of horses against tetanus. The protection afforded by active, passive and combined active-passive methods of immunisation against tetanus was examined in previously unimmunised horses. Three groups of horses were injected; one with tetanus toxoid alone, one with tetanus antitoxin alone and one in which the tetanus toxoid and tetanus antitoxin were injected simultaneously. The protection afforded was determined by monitoring the levels of antitoxin achieved in the horses by each of these methods. The results obtained demonstrated the effectiveness of the combined active-passive method in affording rapid and prolonged pro...